T-cell Lymphoma [Test in Focus] - Insights
Andrew Feldman, M.D., discusses the different tools and techniques Mayo Clinic Laboratories uses to accurately diagnose and classify T-cell lymphomas to help provide clinicians with the diagnostic answers they need to treat their patients.
Gastrointestinal Pathogen Panel, PCR, Feces [Test in Focus] - Insights
The new Gastrointestinal Pathogen Panel, PCR, Feces test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients.
Molecular Detection for Tuberculosis Drug Resistance [Test in Focus] - Insights
Nancy Wengenack, Ph.D. gives an overview of this test available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be...
New Test Options for NTRK Gene Fusions - Insights
The presence NTRK gene fusions is one of the eligibility requirements for the recently FDA-approved therapy Vitrakvi (larotrectinib), a therapy indicated in adult and pediatric patients with solid tumors regardless of the type of tumor....
Notification of Business Name Change to Mayo Clinic Laboratories - Insights
Effective November 9, 2018, our business name will change from Mayo Collaborative Services, LLC, doing business as (d/b/a) Mayo Medical Laboratories to Mayo Collaborative Services, LLC, d/b/a Mayo Clinic Laboratories. The change to Mayo...
Mayo Clinic Laboratory and pathology research roundup: March 15 - Insights
This Feature Includes: Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data.
Mayo Clinic Laboratory and Pathology Research Roundup: April 16 - Insights
This week's research roundup feature: R0 resection and radiation therapy have been associated with improved overall survival (OS) in patients with thymic carcinoma (TC). Here, we analyzed which subgroups of patients derive the greatest...
Mayo Clinic Laboratory and Pathology Research Roundup: February 27 - Insights
This week's research roundup feature: Both targeted therapies and immunotherapies provide benefit in resected Stage III melanoma. We hypothesized that the combination of targeted and immunotherapy given prior to therapeutic lymph node...
CPT codes and LOINC update: May 2024 - Insights
This page includes updates posted to Mayo Clinic Labs during the month of May.
August 2023 - Hematopathology - Insights
This "Pathways" program provides a Clinical Pathology case that includes a history, potential answers, rationale, and relevant references. This case sub-specialty is Hematopathology.